Endosomal Pathway
When viruses enter cells through endocytosis, their nucleic acids are detected in the lumen of the endosomes by a subset of Toll-like receptors (TLRs), including TLR3, TLR7/8, and TLR9. TLR3 detects dsRNAs, TLR7/8 recognize ssRNAs, and TLR9 senses unmethylated CpG DNA (Akira et al., 2006) . These TLRs are synthesized in the ER, where they associate with the transmembrane protein Unc93b1, which escorts the TLR proteins to endosomes (Kim et al., 2008; Tabeta et al., 2006) . For TLR9, and possibly TLR7, their ectodomains must be cleaved by a protease in the endosome before they become functional receptors.
Binding of nucleic acids to TLR7, 8, and 9 leads to the recruitment of the cytosolic adaptor protein MyD88, which in turn recruits the protein kinases IRAK4 and IRAK1. IRAK4 phosphorylates and activates IRAK1, which binds and activates TRAF6 and TRAF3, leading to activation of IKK and TBK1, respectively. In plasmacytoid dendritic cells, the MyD88-IRAK1-TRAF6 complex recruits and activates IRF7, which induces production of IFN-α. Binding of dsRNA to TLR3 triggers recruitment of the adaptor protein TRIF, which in turn recruits TRAF3 and TRAF6 to activate downstream kinases. TRIF also recruits RIP1, a protein kinase involved in NF-κB activation.
Ubiquitin in Antiviral Immunity
Ubiquitination and deubiquitination play pivotal roles in both RLR and TLR pathways of antiviral defense (Bhoj and Chen, 2009) . Following binding to viral RNA, RIG-I is conjugated with Lysine 63 (K63) polyubiquitin chains by the ubiquitin ligases TRIM25 and RNF135. This ubiquitination is apparently important for RIG-I to activate MAVS. Downstream of MAVS, the ubiquitin ligase activity of TRAF3 and TRAF6 also is important for activation of TBK1 and IKK, respectively. Furthermore, K63 polyubiquitination plays an important role in the activation of NF-κB and IRF7 by TRAF6 in the endosomal pathway. Several deubiquitination enzymes (DUBs) function as negative regulators of antiviral responses (Sun, 2008) . The tumor suppressor protein CYLD removes polyubiquitin chains from RIG-I, whereas DUBA cleaves polyubiquitin chains from TRAF3. The anti-inflammatory protein A20 is another DUB that inhibits the RIG-I and TLR pathways at a step upstream of TBK1 and IKK.
Interferon Signaling and Positive Feedback Regulation Type 1 interferons bind to a common receptor composed of two subunits, IFNAR1 and IFNAR2. Engagement of this receptor complex leads to recruitment and activation of the tyrosine kinases JAK1 and TYK2, which phosphorylate the transcription factors STAT1 and STAT2. The activated STAT proteins associate with IRF9 to form a complex called ISGF3, which regulates the expression of a large array of interferon-stimulated genes. The products of these genes act in concert to inhibit viral infection, replication, and assembly. In addition, interferons induce the expression of several key components of the RIG-I pathway, such as RIG-I, TRIM25, and IRF7, thereby amplifying the antiviral response.
Negative Regulation of Antiviral Immunity
After an effective immune response is launched, it must be dampened down or shut down completely in a timely manner to avoid damage to the host. In addition to the DUBs described above, a growing list of host factors has been found to inhibit the RIG-I and TLR pathways. Examples of this list include NLRX1, RNF5, ITCH, MyD88s, and IRAK-M. Pathogens have also evolved strategies to counter the host immune response. For example, hepatitis C virus uses the viral protease NS3/4A to cleave MAVS from the mitochondrial membrane thus blocking induction of type 1 interferon gene expression; this immune evasion strategy assists the virus, enabling it to establish persistent infection in human liver cells. Another example is provided by the influenza A virus, which uses NS1 to inhibit RIG-I activation.
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